Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2021

03.01.2021 | Clinical trial

Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population

verfasst von: Ziyao Li, Ying Wang, Cong Liu, Zhenzhen Wang, Dongmo Wang, Xingyu Liang, Jiawei Tian

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the associations of four commonly studied single nucleotide polymorphisms (SNP) of the vascular endothelial growth factor (VEGF), including -460T/C (rs833061), − 634G/C (rs2010963), − 2578C/A (rs699947), and +936T/C (rs3025039), with the incidence, aggressiveness, and tumor markers expression of breast cancer in the Northern China Han population.

Methods

Followed the genomic DNA extraction, a total of 259 patients with breast cancer (case group) and 273 healthy women (control group) underwent genotyping by PCR-LDR SNP assays. The associations between VEGF gene polymorphisms and the incidence, aggressiveness, and tumor markers expression of breast cancer were analyzed.

Results

Significant differences were observed in allele frequency and genotype distribution of − 634G/C between breast cancer cases and healthy controls (p = 0.006, 0.013). Individuals who carry the G allele more likely had a lower risk of breast cancer (OR, 0.866, 95% CI 0.782–0.959). Compared with CC genotype carriers, women who had the CG and GG genotypes demonstrated a relatively lower risk (OR, 0.860, 95% CI 0.757–0.978, p = 0.022; OR, 0.778, 95% CI, 0.656–0.924, p = 0.004, respectively). When we stratified the group of patients according to the status of tumor markers, a significant association of − 634G/C SNP and Ki-67 expression was observed. The CC genotype carriers were more likely to be characterized by high expression of Ki-67 (p = 0.031). Further analysis showed that the − 460T/-634C/-2578C/+936C haplotype was more associated with a higher risk of breast cancer (OR, 1.445, 95% CI 1.123–1.859, p = 0.004), whereas the − 460T/− 634G/− 2578C/+936C one was associated with a lower risk (OR, 0.736, 95% CI 0.563–0.963, p = 0.025).

Conclusions

In the present study, we concluded that VEGF gene − 634G/C polymorphism is related to the incidence of breast cancer in the Han population in Northern China and also might be associated with tumor proliferation index Ki-67.
Literatur
1.
Zurück zum Zitat Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P (2014) Breast cancer statistics and markers. J Cancer Res Therapeut 10(3):506–511 Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P (2014) Breast cancer statistics and markers. J Cancer Res Therapeut 10(3):506–511
2.
Zurück zum Zitat Su J, Wang J, Luo J, Li H (2019) Ultrasound-mediated destruction of vascular endothelial growth factor (VEGF) targeted and paclitaxel loaded microbubbles for inhibition of human breast cancer cell MCF-7 proliferation. Mol Cell Probes 46:101415CrossRef Su J, Wang J, Luo J, Li H (2019) Ultrasound-mediated destruction of vascular endothelial growth factor (VEGF) targeted and paclitaxel loaded microbubbles for inhibition of human breast cancer cell MCF-7 proliferation. Mol Cell Probes 46:101415CrossRef
3.
Zurück zum Zitat Liu Y, Zhang J, Huang R, Feng WL, Kong YN, Xu F, Zhao L, Song QK, Li J, Zhang BN (2017) Influence of occupation and education level on breast cancer stage at diagnosis, and treatment options in China: a nationwide, multicenter 10-year epidemiological study. Medicine 96(15):e6641CrossRef Liu Y, Zhang J, Huang R, Feng WL, Kong YN, Xu F, Zhao L, Song QK, Li J, Zhang BN (2017) Influence of occupation and education level on breast cancer stage at diagnosis, and treatment options in China: a nationwide, multicenter 10-year epidemiological study. Medicine 96(15):e6641CrossRef
4.
Zurück zum Zitat Al Balawi IA, Mir R, Abu-Duhier FM (2018) Potential impact of vascular endothelial growth factor gene variation (-2578C>A) on breast cancer susceptibility in saudi arabia: a case-control study. Asian Pac J Cancer Prev 19(4):1135–1143PubMedPubMedCentral Al Balawi IA, Mir R, Abu-Duhier FM (2018) Potential impact of vascular endothelial growth factor gene variation (-2578C>A) on breast cancer susceptibility in saudi arabia: a case-control study. Asian Pac J Cancer Prev 19(4):1135–1143PubMedPubMedCentral
5.
Zurück zum Zitat Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, Zheng W (2006) Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 15(6):1148–1152CrossRef Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, Zheng W (2006) Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 15(6):1148–1152CrossRef
6.
Zurück zum Zitat Linderholm B, Tavelin B, Grankvist K, Henriksson R (1998) Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16(9):3121–3128CrossRef Linderholm B, Tavelin B, Grankvist K, Henriksson R (1998) Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16(9):3121–3128CrossRef
7.
Zurück zum Zitat Roy H, Bhardwaj S, Ylä-Herttuala S (2006) Biology of vascular endothelial growth factors. Febs Letters 580(12):2879–2887CrossRef Roy H, Bhardwaj S, Ylä-Herttuala S (2006) Biology of vascular endothelial growth factors. Febs Letters 580(12):2879–2887CrossRef
8.
Zurück zum Zitat Jakubowska A, Gronwald J, Menkiszak J, Górski B, Huzarski T, Byrski T, Edler L, Lubiński J, Scott RJ, Hamann U (2008) The VEGF_936_C>T 3′UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett 262(1):71–76CrossRef Jakubowska A, Gronwald J, Menkiszak J, Górski B, Huzarski T, Byrski T, Edler L, Lubiński J, Scott RJ, Hamann U (2008) The VEGF_936_C>T 3′UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett 262(1):71–76CrossRef
9.
Zurück zum Zitat Su JB, Kim JW, Kang H, Hwang SG, Kim NK (2008) Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C>T) gene and colon cancer in Korea. Anticancer Research 28(2B):1271–1276 Su JB, Kim JW, Kang H, Hwang SG, Kim NK (2008) Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C>T) gene and colon cancer in Korea. Anticancer Research 28(2B):1271–1276
10.
Zurück zum Zitat Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12(8):1232–1235CrossRef Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12(8):1232–1235CrossRef
11.
Zurück zum Zitat Wang K, Peng HL, Li LK (2012) Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Prostate Cancer: a Systematic Review with Meta-analysis. Asian Pacific J Cancer Prevent Apjcp 13(11):5665–5669CrossRef Wang K, Peng HL, Li LK (2012) Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Prostate Cancer: a Systematic Review with Meta-analysis. Asian Pacific J Cancer Prevent Apjcp 13(11):5665–5669CrossRef
12.
Zurück zum Zitat Zhou Y, Li N, Zhuang W, Wu X (2011) Vascular Endothelial Growth Factor (VEGF) Gene Polymorphisms and Gastric Cancer Risk in a Chinese Han Population. Molecular Carcinogenesis 50(3):184–188CrossRef Zhou Y, Li N, Zhuang W, Wu X (2011) Vascular Endothelial Growth Factor (VEGF) Gene Polymorphisms and Gastric Cancer Risk in a Chinese Han Population. Molecular Carcinogenesis 50(3):184–188CrossRef
13.
Zurück zum Zitat Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N, Karakitsos P (2009) Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 48(6):563–569CrossRef Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N, Karakitsos P (2009) Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 48(6):563–569CrossRef
14.
Zurück zum Zitat García-Closas M, Malats N, Real FX, Yeager M, Chanock SJ (2007) Large-scale evaluation of candidate genes identifies associations between VEGF Polymorphisms and bladder cancer risk. Plos Genetics 3(2):e29CrossRef García-Closas M, Malats N, Real FX, Yeager M, Chanock SJ (2007) Large-scale evaluation of candidate genes identifies associations between VEGF Polymorphisms and bladder cancer risk. Plos Genetics 3(2):e29CrossRef
15.
Zurück zum Zitat Su JL, Lee SY, Jeon HS, Sun HP, Park JY (2005) Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prevent 14(3):571–575CrossRef Su JL, Lee SY, Jeon HS, Sun HP, Park JY (2005) Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prevent 14(3):571–575CrossRef
16.
Zurück zum Zitat Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106(4):468–471CrossRef Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106(4):468–471CrossRef
17.
Zurück zum Zitat Jin Q (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res Off J Am Assoc Cancer Res 11(10):3647–3653CrossRef Jin Q (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res Off J Am Assoc Cancer Res 11(10):3647–3653CrossRef
18.
Zurück zum Zitat Rahoui J, Sbitti Y, Touil N, Laraqui A, Ibrahimi A, Rhrab B, Al Bouzidi A, Moussaoui Rahali D, Dehayni M, Ichou M et al (2014) The single nucleotide polymorphism +936 C/T VEGF is associated with human epidermal growth factor receptor 2 expression in Moroccan breast cancer women. Med Oncol 31(12):336CrossRef Rahoui J, Sbitti Y, Touil N, Laraqui A, Ibrahimi A, Rhrab B, Al Bouzidi A, Moussaoui Rahali D, Dehayni M, Ichou M et al (2014) The single nucleotide polymorphism +936 C/T VEGF is associated with human epidermal growth factor receptor 2 expression in Moroccan breast cancer women. Med Oncol 31(12):336CrossRef
19.
Zurück zum Zitat Wang K, Liu L, Zhu ZM, Shao JH, Xin L (2011) Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: a meta-analysis involving 16,703 individuals. Cytokine 56(2):167–173CrossRef Wang K, Liu L, Zhu ZM, Shao JH, Xin L (2011) Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: a meta-analysis involving 16,703 individuals. Cytokine 56(2):167–173CrossRef
20.
Zurück zum Zitat Sa-Nguanraksa D, O-Charoenrat P (2012) The role of vascular endothelial growth factor a polymorphisms in breast cancer. Int J Mol Sci 13(12):14845–14864CrossRef Sa-Nguanraksa D, O-Charoenrat P (2012) The role of vascular endothelial growth factor a polymorphisms in breast cancer. Int J Mol Sci 13(12):14845–14864CrossRef
21.
Zurück zum Zitat Madisen L, Hoar DI, Holroyd CD, Crisp M, Hodes ME, Reynolds JF (1987) The effects of storage of blood and isolated DNA on the integrity of DNA. Am J Med Genet Part A 27(2):379–390CrossRef Madisen L, Hoar DI, Holroyd CD, Crisp M, Hodes ME, Reynolds JF (1987) The effects of storage of blood and isolated DNA on the integrity of DNA. Am J Med Genet Part A 27(2):379–390CrossRef
22.
Zurück zum Zitat Huang K, Tang W, Tang R, Xu Z, He Z, Li Z, Xu Y, Li X, He G, Feng G et al (2008) Positive association between OLIG2 and schizophrenia in the Chinese Han population. Hum Genet 122(6):659–660CrossRef Huang K, Tang W, Tang R, Xu Z, He Z, Li Z, Xu Y, Li X, He G, Feng G et al (2008) Positive association between OLIG2 and schizophrenia in the Chinese Han population. Hum Genet 122(6):659–660CrossRef
23.
Zurück zum Zitat Lelièvre L, Clézardin P, Magaud L, Roche L, Tubiana-Mathieu N, Tigaud JD, Topart D, Raban N, Mouret-Reynier MA, Mathevet P (2018) Comparative study of neoadjuvant chemotherapy with and without zometa for management of locally advanced breast cancer with serum VEGF as primary endpoint: the NEOZOL Study. Clin Breast Cancer 18(6):e1311–e1321CrossRef Lelièvre L, Clézardin P, Magaud L, Roche L, Tubiana-Mathieu N, Tigaud JD, Topart D, Raban N, Mouret-Reynier MA, Mathevet P (2018) Comparative study of neoadjuvant chemotherapy with and without zometa for management of locally advanced breast cancer with serum VEGF as primary endpoint: the NEOZOL Study. Clin Breast Cancer 18(6):e1311–e1321CrossRef
24.
Zurück zum Zitat Kiso M, Tanaka S, Saji S, Toi M, Sato F (2018) Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. Int J Cancer 143(11):2905–2918CrossRef Kiso M, Tanaka S, Saji S, Toi M, Sato F (2018) Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. Int J Cancer 143(11):2905–2918CrossRef
25.
Zurück zum Zitat Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR et al (2013) Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 108(5):1052–1060CrossRef Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR et al (2013) Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 108(5):1052–1060CrossRef
26.
Zurück zum Zitat Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2(10):795–803CrossRef Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2(10):795–803CrossRef
27.
Zurück zum Zitat Morabito A, Sarmiento R, Bonginelli P, Gasparini G (2004) Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Crit Rev Oncol/hematol 49(2):91–107CrossRef Morabito A, Sarmiento R, Bonginelli P, Gasparini G (2004) Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Crit Rev Oncol/hematol 49(2):91–107CrossRef
28.
Zurück zum Zitat Salven P, Perhoniemi V, Tykkä H, Mäenpää H, Joensuu H (1999) Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat 53(2):161–166CrossRef Salven P, Perhoniemi V, Tykkä H, Mäenpää H, Joensuu H (1999) Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat 53(2):161–166CrossRef
29.
Zurück zum Zitat Carpini JD, Karam AK, Montgomery L (2010) Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13(3):279–279CrossRef Carpini JD, Karam AK, Montgomery L (2010) Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13(3):279–279CrossRef
30.
Zurück zum Zitat Ma J, Hu W, Zhang P, Sun Y, Wang N, Teng X, Qiao Q (2015) The association between VEGF +936C/T and -634G/C polymorphisms and breast cancer susceptibility, tumor growth, and metastases: evidence from 20,728 subjects. Cancer Invest 33(7):312–317CrossRef Ma J, Hu W, Zhang P, Sun Y, Wang N, Teng X, Qiao Q (2015) The association between VEGF +936C/T and -634G/C polymorphisms and breast cancer susceptibility, tumor growth, and metastases: evidence from 20,728 subjects. Cancer Invest 33(7):312–317CrossRef
31.
Zurück zum Zitat O-Charoenrat P (2014) Vascular endothelial growth factor polymorphisms affect gene expression and tumor aggressiveness in patients with breast cancer. Mol Med Rep 9(3):1044–1048CrossRef O-Charoenrat P (2014) Vascular endothelial growth factor polymorphisms affect gene expression and tumor aggressiveness in patients with breast cancer. Mol Med Rep 9(3):1044–1048CrossRef
32.
Zurück zum Zitat Sa-Nguanraksa D, Chuangsuwanich T, Pongpruttipan T, Kummalue T, Rojananin S, Ratanawichhitrasin A, Prasarttong-Osoth P, Chuthatisith S, Pisarnturakit P, Aeumrithaicharoenchok W et al (2013) Vascular endothelial growth factor 634G/C polymorphism is associated with increased breast cancer risk and aggressiveness. Mol Med Rep 8(4):1242–1250CrossRef Sa-Nguanraksa D, Chuangsuwanich T, Pongpruttipan T, Kummalue T, Rojananin S, Ratanawichhitrasin A, Prasarttong-Osoth P, Chuthatisith S, Pisarnturakit P, Aeumrithaicharoenchok W et al (2013) Vascular endothelial growth factor 634G/C polymorphism is associated with increased breast cancer risk and aggressiveness. Mol Med Rep 8(4):1242–1250CrossRef
33.
Zurück zum Zitat Zhang H, Sui X, Zhou S, Hu L, Huang X (2019) About Correlation of conventional ultrasound characteristics of breast tumors with axillary lymph node metastasis and ki-67 expression in patients with breast cancer. J Ultrasound Med 38(9):2523CrossRef Zhang H, Sui X, Zhou S, Hu L, Huang X (2019) About Correlation of conventional ultrasound characteristics of breast tumors with axillary lymph node metastasis and ki-67 expression in patients with breast cancer. J Ultrasound Med 38(9):2523CrossRef
34.
Zurück zum Zitat Chung MJ, Lee JH, Kim SH, Suh YJ, Choi HJ (2016) Simple prediction model of axillary lymph node positivity after analyzing molecular and clinical factors in early breast cancer. Med (Baltimore) 95(20):e3689CrossRef Chung MJ, Lee JH, Kim SH, Suh YJ, Choi HJ (2016) Simple prediction model of axillary lymph node positivity after analyzing molecular and clinical factors in early breast cancer. Med (Baltimore) 95(20):e3689CrossRef
35.
Zurück zum Zitat Oliveira C, Lourenço GJ, Silva PMR, Cardoso-Filho C, Favarelli MHC, GonçAles NSL, Gurgel MSC, Lima CSP (2011) Polymorphisms in the 5′- and 3′-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics. Tumor Biol 32(2):295–300CrossRef Oliveira C, Lourenço GJ, Silva PMR, Cardoso-Filho C, Favarelli MHC, GonçAles NSL, Gurgel MSC, Lima CSP (2011) Polymorphisms in the 5′- and 3′-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics. Tumor Biol 32(2):295–300CrossRef
36.
Zurück zum Zitat Luo T, Chen L, He P, Hu QC, Zheng H (2013) Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in a chinese population. Asian Pacific J Cancer Prevent Apjcp 14(4):2433–2437CrossRef Luo T, Chen L, He P, Hu QC, Zheng H (2013) Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in a chinese population. Asian Pacific J Cancer Prevent Apjcp 14(4):2433–2437CrossRef
37.
Zurück zum Zitat Wang K, Liu L, Zhu ZM, Shao JH, Xin L (2011) Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: a meta-analysis involving 16,703 individuals. Cytokine 56(2):167–173CrossRef Wang K, Liu L, Zhu ZM, Shao JH, Xin L (2011) Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: a meta-analysis involving 16,703 individuals. Cytokine 56(2):167–173CrossRef
38.
Zurück zum Zitat Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M (2008) Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 111(1):157–163CrossRef Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M (2008) Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 111(1):157–163CrossRef
39.
Zurück zum Zitat Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ, Calle EE (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8(2):R22CrossRef Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ, Calle EE (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8(2):R22CrossRef
40.
Zurück zum Zitat Langsenlehner U, Wolf G, Langsenlehner T, Gerger A, Hofmann G, Clar H, Wascher TC, Paulweber B, Samonigg H, Krippl P (2008) Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian “tumor of breast tissue: incidence, genetics, and environmental risk factors” study. Breast Cancer Res Treat 109(2):297–304CrossRef Langsenlehner U, Wolf G, Langsenlehner T, Gerger A, Hofmann G, Clar H, Wascher TC, Paulweber B, Samonigg H, Krippl P (2008) Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian “tumor of breast tissue: incidence, genetics, and environmental risk factors” study. Breast Cancer Res Treat 109(2):297–304CrossRef
Metadaten
Titel
Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population
verfasst von
Ziyao Li
Ying Wang
Cong Liu
Zhenzhen Wang
Dongmo Wang
Xingyu Liang
Jiawei Tian
Publikationsdatum
03.01.2021
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2021
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-06024-3

Weitere Artikel der Ausgabe 1/2021

Breast Cancer Research and Treatment 1/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.